Targeted Genetics Appoints David J. Poston as Chief Financial Officer
19 1월 2006 - 5:02AM
Business Wire
Targeted Genetics Corporation (Nasdaq:TGEN) announced today the
appointment of David J. Poston as Vice President, Finance, Chief
Financial Officer, and Treasurer. Mr. Poston has been serving as
the acting Chief Financial Officer at Targeted Genetics since
October 2005 and has been a key part of the company's finance
organization since January 1999. "David has made significant
contributions to our progress during his seven years with the
company and his more than twenty years of financial experience make
him a natural choice as CFO," said H. Stewart Parker, President and
Chief Executive Officer of Targeted Genetics. "Having David as a
tenured financial resource to the management team is extremely
important as we continue to advance our product pipeline, enter
into strategic collaborations and consider capital-raising
opportunities." David J. Poston, 42, previously served as the
company's senior director of finance and accounting from 2001
through 2005 and as the finance director from 1999 to 2001. Prior
to joining Targeted Genetics, he served as controller of Corixa
Corporation, controller and assistant treasurer of Todd Shipyards
Corporation and in financial management capacities at Rocket
Research Corporation (now General Dynamics). Mr. Poston has over
twenty years of financial experience, has had primary
responsibility for public company financial disclosure matters
since 1993 and started his career in public accounting at KPMG in
1985. Mr. Poston graduated from the University of Puget Sound with
a B.S. in accounting, a minor in mathematics and as the Norton
Clapp Arete Scholar. About Targeted Genetics Targeted Genetics
Corporation is a biotechnology company committed to the development
and commercialization of innovative targeted molecular therapies
for the prevention and treatment of inflammatory arthritis,
HIV/AIDS and other acquired and inherited diseases with significant
unmet medical need. Targeted Genetics uses its considerable
knowledge and capabilities in the development and manufacturing of
gene delivery technologies to advance a diverse product development
pipeline. Its product development efforts target inflammatory
arthritis, HIV/AIDS, congestive heart failure, Huntington's
disease, and hyperlipidemia. To learn more about Targeted Genetics,
visit its website at www.targetedgenetics.com. Safe Harbor
Statement under the Private Securities Litigation Reform Act of
1995: This release contains forward-looking statements regarding
our business strategy, our product development, our personnel and
other statements about our plans, objectives, intentions and
expectations. In particular, the statements regarding the Company's
future plans are forward-looking statements. These statements,
involve current expectations, forecasts of future events and other
statements that are not historical facts. Inaccurate assumptions
and known and unknown risks and uncertainties can affect the
accuracy of forward-looking statements. Factors that could affect
our actual results include, but are not limited to, the timing,
nature and results of our clinical trials, potential development of
alternative technologies or more effective products by competitors,
our ability to obtain and maintain regulatory or institutional
approvals, our ability to obtain, maintain and protect our
intellectual property and our ability to raise capital when needed,
as well as other risk factors described in the section entitled
"Factors Affecting Our Operating Results, Our Business and Our
Stock Price" in our Quarterly Report on Form 10-Q for the period
ended September 30, 2005. You should not rely unduly on these
forward-looking statements, which apply only as of the date of this
release. We undertake no duty to publicly announce or report
revisions to these statements as new information becomes available
that may change our expectations.
Tecogen (NASDAQ:TGEN)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Tecogen (NASDAQ:TGEN)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024